158
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML

ORCID Icon, , , , , , , , , ORCID Icon, , , , & show all
Pages 3257-3260 | Received 26 May 2022, Accepted 23 Aug 2022, Published online: 08 Sep 2022
 

Acknowledgements

The authors would like to thank Lois Malehorn for editorial assistance.

Disclosure statement

Annie Im has performed consulting from Abbvie and CTI Biopharma and received research funding from Incyte. Alison Sehgal has received research funding from Kite/Gilead, Juno/BMS and Milltenyiz. Michael Boyiadzis is currently an adjunct professor of Medicine at the University of Pittsburgh and an employee of Genentech.

Additional information

Funding

K.L. is supported by the NIH TL1 TR001858. This work is supported by the National Center for Advancing Translational Sciences. This work utilized the Hillman Cancer Center Biostatistics Facility, a shared resource at the University of Pittsburgh supported by the CCSG P30CA047904.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.